Matej Andelic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Matej Andelic has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Signe Holm Nielsen
Immunoscience, Nordic Bioscience, Herlev, Denmark
3 shared publicationsSimon Francis Thomsen
Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
3 shared publications- Aleksander Moldt Haack
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark
1 shared publication Alexander Egeberg
Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark, Department of Clinical Medicine, University of Copenhagen, Denmark
1 shared publication- Alexander Nyström
Department of Dermatology, Medical Faculty, Medical Center - University of Freiburg, Freiburg, Germany
1 shared publication Anne-Christine Bay-Jensen
Immunoscience, Nordic Bioscience, Herlev, Denmark
1 shared publication
Latest Publications
- Open Access
- 11 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A novel immunoassay for neostatin-7 quantifies basement membrane remodeling and reveals an association with reduced pulmonary function in systemic sclerosis
Systemic sclerosis (SSc) is characterized by immune dysregulation, vasculopathy, and excessive extracellular matrix remodeling. Type XVIII collagen in the basement membrane undergoes proteolytic cleavage generating bioactive fragments such as neostatin-7. This study aimed to develop and validate a novel ELISA, NEO7, targeting neostatin-7, an MMP-generated fragment of type XVIII collagen, and to evaluate its clinical relevance in SSc. The competitive ELISA was developed using a monoclonal antibody directed against neostatin-7-specific cleavage site. Technical evaluation included assessments of specificity, precision, accuracy, interference, and stability. Clinical evaluation was performed in serum from 102 SSc patients and 42 healthy controls. The NEO7 assay showed robust technical performance, and levels were significantly elevated in SSc patients compared to healthy controls (p < 0.01). NEO7 was not associated with proximal skin thickening (p = 0.08), defined as skin thickening proximal to metacarpophalangeal joints, but was higher in patients with airway restriction (forced vital capacity < 80%, p < 0.01). ROC analysis demonstrated moderate discrimination of airway restriction (AUROC = 0.70). NEO7 correlated positively with C-reactive protein (r = 0.34, p < 0.01) and was lower in patients receiving immunomodulatory therapy (p < 0.05). These findings identify NEO7 as a candidate biomarker of basement membrane remodeling in SSc.
- 11 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA novel immunoassay for neostatin-7 quantifies basement membrane remodeling and reveals an association with reduced pulmonary function in systemic sclerosis
Systemic sclerosis (SSc) is characterized by immune dysregulation, vasculopathy, and excessive extracellular matrix remodeling. Type XVIII collagen in the basement membrane undergoes proteolytic cleavage generating bioactive fragments such as neostatin-7. This study aimed to develop and validate a novel ELISA, NEO7, targeting neostatin-7, an MMP-generated fragment of type XVIII collagen, and to evaluate its clinical relevance in SSc. The competitive ELISA was developed using a monoclonal antibody directed against neostatin-7-specific cleavage site. Technical evaluation included assessments of specificity, precision, accuracy, interference, and stability. Clinical evaluation was performed in serum from 102 SSc patients and 42 healthy controls. The NEO7 assay showed robust technical performance, and levels were significantly elevated in SSc patients compared to healthy controls (p < 0.01). NEO7 was not associated with proximal skin thickening (p = 0.08), defined as skin thickening proximal to metacarpophalangeal joints, but was higher in patients with airway restriction (forced vital capacity < 80%, p < 0.01). ROC analysis demonstrated moderate discrimination of airway restriction (AUROC = 0.70). NEO7 correlated positively with C-reactive protein (r = 0.34, p < 0.01) and was lower in patients receiving immunomodulatory therapy (p < 0.05). These findings identify NEO7 as a candidate biomarker of basement membrane remodeling in SSc.
- Open Access
- 4 August 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (8) , e70089
Genetic and Environmental Contributions to Serological Biomarkers of Extracellular Matrix Remodeling in Asthma: A Twin Study
Background: Asthma is characterized by airway obstruction driven by chronic inflammation, leading to extracellular matrix (ECM) remodeling. This involves ECM alterations, including increased collagen deposition and elastolysis, resulting in airway wall thickening and irreversible airflow limitation. Despite ECM remodeling's known role in asthma, no reliable tools track these changes, and the genetic and environmental factors driving them remain unclear.Objective: This study investigated ECM remodeling in asthma by assessing 12 serological neo‐epitopes related to collagen synthesis, degradation, and immune cell activity. Studying monozygotic (MZ) and dizygotic (DZ) twins, we explored genetic and environmental influences on ECM changes.Methods: The study included 512 individuals from 256 twin pairs (89 MZ, 167 DZ), of which 200 were healthy and 312 had asthma. An exploratory panel of 12 ECM biomarkers reflecting type III and VI collagen formation (PRO‐C3, PRO‐C6), turnover (PRO‐C4), degradation (C3M, C4M, C4Mα3, C6M, C7M), and immune cell activity (VICM, ELP‐3, ELA‐HNE, CC16‐HNE) was measured in serum using ELISA.Results: Asthma was linked to increased type IV collagen degradation (C4M). Airway obstruction showed decreased PRO‐C6, C4Mα3, C6M, and C7M, while C4M and ELP‐3 were elevated among twins. Classical twin analyses revealed genetic influence on multiple biomarkers, primarily C4Mα3, C7M, CC16‐HNE, and VICM.Conclusion: This study highlights ECM remodeling's role in asthma and airway obstruction, identifying distinct biomarker profiles. Genetic factors significantly influence ECM changes, suggesting potential genetic predispositions for ECM alterations and offering insights into asthma pathogenesis and future diagnostic and therapeutic strategies.
- 4 August 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (8) , e70089
Open AccessGenetic and Environmental Contributions to Serological Biomarkers of Extracellular Matrix Remodeling in Asthma: A Twin Study
Background: Asthma is characterized by airway obstruction driven by chronic inflammation, leading to extracellular matrix (ECM) remodeling. This involves ECM alterations, including increased collagen deposition and elastolysis, resulting in airway wall thickening and irreversible airflow limitation. Despite ECM remodeling's known role in asthma, no reliable tools track these changes, and the genetic and environmental factors driving them remain unclear.Objective: This study investigated ECM remodeling in asthma by assessing 12 serological neo‐epitopes related to collagen synthesis, degradation, and immune cell activity. Studying monozygotic (MZ) and dizygotic (DZ) twins, we explored genetic and environmental influences on ECM changes.Methods: The study included 512 individuals from 256 twin pairs (89 MZ, 167 DZ), of which 200 were healthy and 312 had asthma. An exploratory panel of 12 ECM biomarkers reflecting type III and VI collagen formation (PRO‐C3, PRO‐C6), turnover (PRO‐C4), degradation (C3M, C4M, C4Mα3, C6M, C7M), and immune cell activity (VICM, ELP‐3, ELA‐HNE, CC16‐HNE) was measured in serum using ELISA.Results: Asthma was linked to increased type IV collagen degradation (C4M). Airway obstruction showed decreased PRO‐C6, C4Mα3, C6M, and C7M, while C4M and ELP‐3 were elevated among twins. Classical twin analyses revealed genetic influence on multiple biomarkers, primarily C4Mα3, C7M, CC16‐HNE, and VICM.Conclusion: This study highlights ECM remodeling's role in asthma and airway obstruction, identifying distinct biomarker profiles. Genetic factors significantly influence ECM changes, suggesting potential genetic predispositions for ECM alterations and offering insights into asthma pathogenesis and future diagnostic and therapeutic strategies.
- Open Access
- 9 July 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (11) , 2118-2132
Extracellular matrix alterations in inflammatory skin diseases: emerging biomarkers and clinical implications
The interaction among extracellular matrix (ECM) components (proteoglycans, elastin, laminins, collagens and metalloproteinases) is important for maintaining homeostasis of the skin. However, in chronic inflammatory diseases, tissue homeostasis is disrupted by having an uncontrolled remodelling of the ECM, resulting in an imbalance of its composition and functionality. In these pathologies, there is a dysregulation of the immune system characterized by recurrent itching, pain and inflammation in affected areas of the skin. Three of the most common inflammatory skin diseases are hidradenitis suppurativa, psoriasis and atopic dermatitis, with worldwide prevalence of 1%, 3% and 15%, respectively. The shared pathological characteristic for these diseases is an altered skin tissue structure, characterized by an excessive remodelling of ECM proteins. Despite well-documented evidence of ECM alterations in these pathologies, biomarkers reflecting ECM remodelling to aid drug development and potential treatment targets have been overlooked. There is therefore an unmet need to develop biomarkers for predicting outcomes and selecting treatment for individual patients. This review focuses on ECM dysregulation in inflammatory skin diseases, with a focus on how biomarkers can predict outcomes and monitor drug efficacy.
- 9 July 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (11) , 2118-2132
Open AccessExtracellular matrix alterations in inflammatory skin diseases: emerging biomarkers and clinical implications
The interaction among extracellular matrix (ECM) components (proteoglycans, elastin, laminins, collagens and metalloproteinases) is important for maintaining homeostasis of the skin. However, in chronic inflammatory diseases, tissue homeostasis is disrupted by having an uncontrolled remodelling of the ECM, resulting in an imbalance of its composition and functionality. In these pathologies, there is a dysregulation of the immune system characterized by recurrent itching, pain and inflammation in affected areas of the skin. Three of the most common inflammatory skin diseases are hidradenitis suppurativa, psoriasis and atopic dermatitis, with worldwide prevalence of 1%, 3% and 15%, respectively. The shared pathological characteristic for these diseases is an altered skin tissue structure, characterized by an excessive remodelling of ECM proteins. Despite well-documented evidence of ECM alterations in these pathologies, biomarkers reflecting ECM remodelling to aid drug development and potential treatment targets have been overlooked. There is therefore an unmet need to develop biomarkers for predicting outcomes and selecting treatment for individual patients. This review focuses on ECM dysregulation in inflammatory skin diseases, with a focus on how biomarkers can predict outcomes and monitor drug efficacy.
- 1 April 2025
- Published by JLE in European Journal Of Dermatology
- Vol. 35 (2) , 91-97
A novel biomarker of type VII collagen degradation increases in patients with atopic dermatitis and decreases upon treatment with immunosuppressants
Remodelling of the extracellular matrix (ECM) is a continuous process necessary for maintaining skin tissue architecture and function. Disruption of type VII and XVII collagen turnover within the ECM is a contributing factor in the pathogenesis of skin conditions such as atopic dermatitis (AD). To investigate the turnover of type VII and XVII collagens in AD using novel biomarkers of ECM turnover. Type VII (C7M) and XVII (PRO-C17) collagen turnover were measured using ELISAs. The cohort comprised 158 AD patients and 20 matched healthy donors (HD), with 53 of the AD patients treated with topical calcineurin inhibitors. Disease severity was assessed using the SCORAD index, categorizing patients into mild (SCORAD < 25), moderate (SCORAD: 25-50), and severe (SCORAD > 50) groups. AD patients across all severity groups had higher C7M levels (all: p < 0.0001), while the levels of PRO-C17 were higher in mild AD patients versus HD (p = 0.0399). The C7M marker demonstrated an AUC of 0.96, and its levels were decreased in AD patients undergoing topical calcineurin inhibitor treatment (p=0.0073). The turnover of type VII and XVII collagens, measured by the biomarkers C7M and PRO-C17, is elevated in patients with AD. The biomarker C7M may have the potential to serve as a diagnostic and treatment response biomarker in AD.
- 1 April 2025
- Published by JLE in European Journal Of Dermatology
- Vol. 35 (2) , 91-97
A novel biomarker of type VII collagen degradation increases in patients with atopic dermatitis and decreases upon treatment with immunosuppressants
Remodelling of the extracellular matrix (ECM) is a continuous process necessary for maintaining skin tissue architecture and function. Disruption of type VII and XVII collagen turnover within the ECM is a contributing factor in the pathogenesis of skin conditions such as atopic dermatitis (AD). To investigate the turnover of type VII and XVII collagens in AD using novel biomarkers of ECM turnover. Type VII (C7M) and XVII (PRO-C17) collagen turnover were measured using ELISAs. The cohort comprised 158 AD patients and 20 matched healthy donors (HD), with 53 of the AD patients treated with topical calcineurin inhibitors. Disease severity was assessed using the SCORAD index, categorizing patients into mild (SCORAD < 25), moderate (SCORAD: 25-50), and severe (SCORAD > 50) groups. AD patients across all severity groups had higher C7M levels (all: p < 0.0001), while the levels of PRO-C17 were higher in mild AD patients versus HD (p = 0.0399). The C7M marker demonstrated an AUC of 0.96, and its levels were decreased in AD patients undergoing topical calcineurin inhibitor treatment (p=0.0073). The turnover of type VII and XVII collagens, measured by the biomarkers C7M and PRO-C17, is elevated in patients with AD. The biomarker C7M may have the potential to serve as a diagnostic and treatment response biomarker in AD.